Anthony G.
- Country
- France
- Department
- Medical oncology
Research Overview
- ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis.
- De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy
- Phase 3 Randomized Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in HR+/HER2- Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 292 of 574 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in treating advanced forms of triple-negative breast cancer (TNBC), with particular focus on cases that are either locally recurrent, inoperable, or have developed metastatic characteristics.
- Advanced TNBC Management
- Metastatic Disease Treatment
- Locally Recurrent Cancer Care
Immunotherapy Expertise
The investigator focuses on innovative therapeutic approaches combining immunotherapy agents for breast cancer treatment, particularly exploring the integration of durvalumab and oleclumab in treatment protocols.
- Combined Immunotherapy Approaches
- Novel Treatment Combinations
- Immune Response Modulation
Chemotherapy Integration
The investigator has developed expertise in combining traditional chemotherapy agents like paclitaxel and carboplatin with newer immunotherapeutic approaches for treating aggressive breast cancers.
- Combination Therapy Protocols
- Treatment Safety Assessment
- Clinical Benefit Evaluation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.